Eden Biodesign - - BioPharm International


Eden Biodesign

BioPharm International
Volume 19, Issue 12

Company Description

Eden Biodesign is a biologics contract manufacturer and fully integrated biopharmaceutical development organization whose role is to design, develop and deliver valuable biopharmaceutical medicines.

Its motto is "begin with the end in mind"—a distillation of its experience gained over many years working with biotech and CMO clients.

Eden Biodesign grew out of a successful, international consultancy business with some of the most experienced people in the biotech industry.

Biopharmaceutical Techniques Supported

Eden Biodesign has expertise across all stages of product development, from expression system development to clinical trial supply logistics, and at all stages of product development, from proof of concept to post license variations.

Eden Biodesign has the capacity to provide world-class manufacturing services for mammalian, microbial and virus biopharmaceutical product technologies.

Markets Served

Eden Biodesign serves clients throughout Europe, USA, Asia, and Australasia and works with large biopharmaceutical companies, small-to-medium size biotech companies, university spin-outs, and major charity organizations.

Products and Services

Process development and manufacturing services

Our principal services include expression system development, analytical development, process development, clinical trial manufacturing and quality assurance.

Consultancy services

In addition to our core development and manufacturing activities, we offer:

  • Strategic advice: performing due diligence for biopharmaceutical in or out licensing, advising on facility design and operations and producing product development and manufacturing plans.
  • Training: offering tailored training packages which cover the whole spectrum of biopharmaceutical development and manufacturing disciplines.
  • Regulatory advice: our experienced consultants have the appropriate skills to assist you in negotiating the many regulatory hurdles that can stand in the way of clinical and commercial success.


We are the operators of the UK National Biomanufacturing Centre in Liverpool—a 4100 sq. ft. facility that includes:

  • 3 dedicated process development suites
  • 6 separated quality control and analytical testing laboratories
  • 3 segregated cGMP suites designed for rapid, flexible and robust manufacturing for up to 200L for mammalian, 100L for microbial and 20L for viral products

Our facility is designed to be fully compliant with EU and USA cGMP guidelines.

The flexibility and adaptability of the suites ensure that there are few biotech-based products that we cannot manufacture.

National Biomanufacturing Centre, Estuary Banks, Estuary Commerce Park, Speke Road
Liverpool, UK L24 8RB







blog comments powered by Disqus



FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here